Phaseline

Companies › Lubris Bio

Lubris Bio: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 2; Ophthalmology, Immunology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
rhPRG4
Recombinant human proteoglycan 4 (lubricin)
PRG4Phase 2Sjögren's SyndromeDec 2026
rhPRG4 450 μg/ml
Recombinant human proteoglycan 4 (lubricin analog)
PRG4Phase 2Ocular Graft Versus Host DiseaseMar 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07118241rhPRG4Phase 2Sjögren's SyndromeImmunologyDec 2026
NCT07118254rhPRG4 450 μg/mlPhase 2Ocular Graft Versus Host DiseaseOphthalmologyMar 2027

Targets

PRG4 (2)

Companies with the same targets

–

Companies built like this

MRM Health Triveni Bio Citryll Priovant Therapeutics Vantage Biosciences

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.